A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

Qu et al., NCT04622332, NCT04622332, Nov 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/qu3.html

Pilot RCT 42 hospitalized COVID-19 patients showing no significant differences with SIR1-365 treatment. foo

Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.

Important missing comments or errors? Let us know.

risk of no recovery, 87.5% higher, RR 1.88, p = 0.44, treatment median 1.6 range 0.0-27.7 n=23, control median 3.0 range 0.0-22.0 n=19, relative days without oxygen, day 28.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. c19early.org, c19early.org/soc/usa.html.

Qu et al., 27 Nov 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04622332 (history). Contact: Lisa.Fitzgerald@sironax.com.

This Paper SIR1-365 All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0